Company news

Nanjing Leads Biolabs Co., Ltd. news in 2025

Nanjing Leads Biolabs Co., Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

December 23, 2025

Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting

December 7, 2025

Oral Presentation: Five Hematologic Malignancies Studies by Leads Biolabs to Be Featured at ASH 2025

November 3, 2025

First-in-Class Potential! FDA Clears IND Application for LBL-047, an Anti-BDCA2/TACI Bispecific Fusion Protein Developed by Leads Biolabs

September 22, 2025

Indication Expansion Accelerates: First Patient Dosed in Melanoma Phase 1b/II Trial of Opamtistomig

September 12, 2025

Acceleration in Clinical Development! Leads Biolabs' LBL-034 Dosed First Patient in Phase Ⅱ Trial

August 25, 2025

Leads Biolabs Announces Completion of Patient Enrollment in Pivotal Trial of Opamtistomig Monotherapy for Extrapulmonary Neuroendocrine Carcinoma

August 14, 2025

Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering

July 24, 2025

Decks in 2025